Premium accounts now available! Sign up and create a premium account. Read more Close

Your cookie settings

This site uses cookies. Some cookies are essential to make the site work and others help us to improve our services. Read more about cookies in our Privacy policy.

Choose your cookie preferences:

Advertisement

Image

[Articles] Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial

Journal content Created on 28 Jul 2026 The Lancet Oncology

Mark D Tyson, Jong-Kil Nam, Shreyas S Joshi, Edward M Uchio, Seung Il Jung, Trinity J Bivalacqua, Gary D Steinberg, Neal D Shore, James M Burke, Hiroshi Kitamura, Ben Tran, Roger Li

Advertisement

Stats

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 35
  • Comments 0

Recommended by

  • No recommendations yet.

Do you recommend this? Please sign in. Yes No

Recommended

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement